| CTNT 0.04 -10.11% | ALP 0.23 -17.86% | FFAI 0.4232 -20.44% | TZA 5.04 -1.95% | BYND 1.1 5.26% | SOXS 16.8 -7.69% | NVDA 202.5 1.31% | NOK 9.825 -5.53% | BITO 10.82 5.15% | INTC 65.27 -1.49% | POET 12.77 24.59% | NVTS 18.47 20.48% | AGPU 8.75 79.30% | BMNG 1.64 14.69% | QVCGA 0.447 11.06% | TQQQ 60.21 4.90% | ONDS 11.06 1.75% | PLUG 3.19 3.57% | ASBP 0.2224 13.01% | AAL 11.5 -2.29% | BURU 0.2811 8.03% | CGC 1.38 21.05% | SOXL 105.64 7.70% | MSOS 5.11 19.39% | SMR 13.58 16.37% | FRMI 5.86 15.81% | TSLA 387.51 0.28% | T 25.97 0.35% | SQQQ 54.73 -4.97% | MARA 11.84 5.43% | IBIT 44.75 5.27% | AMD 303.46 6.67% | TDTH 0.0774 3.48% | BMNR 23.31 7.37% | TSLL 12.93 0.47% | NVD 5.56 -2.63% | MU 487.48 8.48% | SOFI 19.06 1.22% | PLTR 152.62 4.56% | OPEN 5.43 -0.37% | AAPL 273.17 2.63% | GAME 0.6069 33.86% | GPUS 0.1712 11.17% | SPY 711.21 1.01% | BSX 64.87 8.99% | AKAN 10.21 214.15% | SPDN 9.11 -0.98% | GRAB 4.06 -0.49% | BBD 4.04 -0.74% | CPNG 20.6 0.93%

Barclays Downgrades Medpace To Underweight, Cites Valuation Concerns

Barclays downgraded Medpace Holdings Inc. (NASDAQ: MEDP) from Equalweight to Underweight and reduced its price target to $425.00 from $450.00.

The firm said the downgrade was primarily valuation-driven, noting that Medpace shares were trading well above the premium historically enjoyed relative to peers. While the biotech market was described as “bouncing along the bottom,” Barclays said it expected the company to continue winning new business.

However, the firm flagged potential risk in the second half of 2026, citing concern over whether Medpace could fill its backlog with faster-burning projects to sustain elevated growth as more traditional work ramps.

Published on: October 2, 2025